

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number
WO 2005/002552 A2

(51) International Patent Classification⁷: A61K 31/00

(21) International Application Number:
PCT/GB2004/002824

(22) International Filing Date: 5 July 2004 (05.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0315657.7 3 July 2003 (03.07.2003) GB
60/484,685 3 July 2003 (03.07.2003) US
60/514,374 24 October 2003 (24.10.2003) US
0324919.0 24 October 2003 (24.10.2003) GB

(71) Applicant (for all designated States except US): ASTEX
TECHNOLOGY LIMITED [GB/GB]; 436 Cambridge
Science Park, Milton Road, Cambridge CB4 0QA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BERDINI, Valerio
[IT/GB]; 436 Cambridge Science Park, Milton Road,
Cambridge CB4 0QA (GB). O'BRIEN, Michael, Alistair
[GB/GB]; 436 Cambridge Science Park, Milton Road,
Cambridge CB4 0QA (GB). CARR, Maria, Grazia


[GB/GB]; 436 Cambridge Science Park, Milton Road,
Cambridge CB4 0QA (GB). EARLY, Theresa, Rachel
[GB/GB]; 436 Cambridge Science Park, Milton Road,
Cambridge CB4 0QA (GB). NAVARRO, Eva, Figueroa
[ES/GB]; 436 Cambridge Science Park, Milton Road,
Cambridge CB4 0QA (GB). GILL, Adrian, Liam
[GB/GB]; 436 Cambridge Science Park, Milton Road,
Cambridge CB4 0QA (GB). HOWARD, Steven [GB/GB];
436 Cambridge Science Park, Milton Road, Cambridge
CB4 0QA (GB). TREWARTHA, Gary [GB/GB]; 436
Cambridge Science Park, Milton Road, Cambridge CB4
0QA (GB). WOOLFORD, Alison, Jo-Anne [GB/GB];
436 Cambridge Science Park, Milton Road, Cambridge
CB4 0QA (GB). WOODHEAD, Andrew, James
[GB/GB]; 436 Cambridge Science Park, Milton Road,
Cambridge CB4 0QA (GB). WYATT, Paul [GB/GB]; 436
Cambridge Science Park, Milton Road, Cambridge CB4
0QA (GB).

(74) Agent: HUTCHINS, Michael, Richard; M.R. Hutchins
& Co., 23 Mount Sion, Tunbridge Wells, Kent TN1 1TZ
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

[Continued on next page]

(54) Title: PHARMACEUTICAL COMPOUNDS



(57) Abstract: The invention provides compounds having activity as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases. The compounds have the general formula (I); wherein X is CR⁵ or N; A is a bond or -(CH₂)_m-(B)_n-; B is C=O, NR⁸(C=O) or O(C=O) wherein R⁸ is hydrogen or C₁₋₄ hydrocarbyl optionally substituted by hydroxy or C₁₋₄ alkoxy; m is 0, 1 or 2; n is 0 or 1; R⁰ is hydrogen or, together with NR⁸ when present, forms a group -(CH₂)_p- wherein p is 2 to 4; R¹ is hydrogen, a carbocyclic or heterocyclic group having from 3 to 12 ring members, or an optionally substituted C₁₋₈ hydrocarbyl group; R² is hydrogen, halogen, methoxy, or a C₁₋₄ hydrocarbyl group optionally substituted by halogen, hydroxyl or methoxy; R³ and R⁴ together with the carbon atoms to which they are attached form an optionally substituted fused carbocyclic or heterocyclic ring having from 5 to 7 ring members of which up to 3 can be heteroatoms selected from N, O and S; and R⁵ is hydrogen, a group R² or a group R¹⁰ wherein R¹⁰ is selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b wherein R^a is a bond, O, CO, X¹C(X²), C(X²)X¹, X¹C(X²)X¹, S, SO, SO₂, NR^c, SO₂NR^c or NR^cSO₂; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C₁₋₈ hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, X¹C(X²), C(X²)X¹ or X¹C(X²)X¹; R^c is selected from hydrogen and C₁₋₄ hydrocarbyl; and X¹ is O, S or NR^c and X² is =O, =S or =NR^c. Also included within formula (I) are the salts, solvates and N-oxides of the compounds.



AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.